A macro-micro-macro radiogenomic framework identifies FIBCD1 as a key immune-modulating biomarker in breast cancer.

ABSTRACT:

Background

Breast cancer prognosis remains challenging due to tumor heterogeneity and the limited predictive power of conventional clinical models. Integrating imaging features with molecular data may improve individualized risk stratification and clinical decision-making.

Methods

We developed a closed-loop prognostic model based on a macro-micro-macro radiogenomic framework that combines MRI-based radiomics with transcriptomic and proteomic data. A total of 788 radiomics-guided candidate genes were screened. Prognostic gene signatures were identified using multiple machine learning algorithms and validated in TCGA and GEO cohorts. We further analyzed immune infiltration, drug sensitivity, and gene enrichment profiles across risk groups. Causal relationships between gene exp

SUBMITTER: Hong M 

PROVIDER: S-EPMC12649031 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature